BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 35142156)

  • 21. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
    Rayes J; Hollestelle MJ; Legendre P; Marx I; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Blood; 2010 Jun; 115(23):4870-7. PubMed ID: 20200350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway.
    Bury L; Falcinelli E; Mezzasoma AM; Guglielmini G; Momi S; Gresele P
    Haematologica; 2022 Jul; 107(7):1643-1654. PubMed ID: 34407603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
    Hulstein JJ; de Groot PG; Silence K; Veyradier A; Fijnheer R; Lenting PJ
    Blood; 2005 Nov; 106(9):3035-42. PubMed ID: 16014562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How I treat type 2B von Willebrand disease.
    Kruse-Jarres R; Johnsen JM
    Blood; 2018 Mar; 131(12):1292-1300. PubMed ID: 29378695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val.
    Doggett TA; Girdhar G; Lawshe A; Miller JL; Laurenzi IJ; Diamond SL; Diacovo TG
    Blood; 2003 Jul; 102(1):152-60. PubMed ID: 12637314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.
    Deng W; Wang Y; Druzak SA; Healey JF; Syed AK; Lollar P; Li R
    J Thromb Haemost; 2017 Sep; 15(9):1867-1877. PubMed ID: 28692141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
    Cooney KA; Ginsburg D
    Blood; 1996 Mar; 87(6):2322-8. PubMed ID: 8630394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
    Dupont A; Soukaseum C; Cheptou M; Adam F; Nipoti T; Lourenco-Rodrigues MD; Legendre P; Proulle V; Rauch A; Kawecki C; Bryckaert M; Rosa JP; Paris C; Ternisien C; Boisseau P; Goudemand J; Borgel D; Lasne D; Maurice P; Lenting PJ; Denis CV; Susen S; Kauskot A
    Haematologica; 2019 Dec; 104(12):2493-2500. PubMed ID: 30819911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
    Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
    J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B.
    Nurden P; Gobbi G; Nurden A; Enouf J; Youlyouz-Marfak I; Carubbi C; La Marca S; Punzo M; Baronciani L; De Marco L; Vitale M; Federici AB
    Blood; 2010 Apr; 115(13):2649-56. PubMed ID: 20118404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized GPIbα-von Willebrand factor interaction in the mouse.
    Kanaji S; Orje JN; Kanaji T; Kamikubo Y; Morodomi Y; Chen Y; Zarpellon A; Eberhardt J; Forli S; Fahs SA; Sood R; Haberichter SL; Montgomery RR; Ruggeri ZM
    Blood Adv; 2018 Oct; 2(19):2522-2532. PubMed ID: 30287479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Ibα.
    Ju L; Dong JF; Cruz MA; Zhu C
    J Biol Chem; 2013 Nov; 288(45):32289-32301. PubMed ID: 24062306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes.
    Othman M
    Semin Thromb Hemost; 2007 Nov; 33(8):780-6. PubMed ID: 18175283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.
    Casari C; Du V; Wu YP; Kauskot A; de Groot PG; Christophe OD; Denis CV; de Laat B; Lenting PJ
    Blood; 2013 Oct; 122(16):2893-902. PubMed ID: 23945153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.
    Wohner N; Legendre P; Casari C; Christophe OD; Lenting PJ; Denis CV
    J Thromb Haemost; 2015 May; 13(5):815-20. PubMed ID: 25728415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
    Guermazi S; Conard J; Samama MM; Dellagi K
    Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.